U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Tel: 1 (862) 261-7000
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
Please click here for clinical trial information.
912 articles with Allergan, Inc.
Allergan Release: FDA Accepts NDA for Seysara (Sarecycline) for the Treatment of Moderate to Severe Acne
Allergan and Paratek Pharma today announced that the FDA has accepted a NDA to review Seysara for the treatment of moderate to severe acne vulgaris in patients 9 years of age and older.
In this study, the primary efficacy objective was met for both Cariprazine 1.5mg and 3mg dose groups.
Wayne Swanton will join Allergan's Executive Leadership Team and maintain responsibility for Global Manufacturing, Quality, Supply Chain, Procurement, Pharmaceutical Technology, Operational Excellence, Engineering, Environmental Health & Safety and Security.
The possibility of a tax bill being passed has many investors and analysts forecasting 2018 to be a big year for mergers and acquisitions.
The deal is expected to close in the first quarter of 2018.
An 18-week trial found that 77% of patients showed improved appearance of lax tissue and 75% of patients reported their chin looked more toned following treatment.
Allergan Receives FDA Approval for Use of VRAYLAR (cariprazine) in the Maintenance Treatment of Schizophrenia
The efficacy of VRAYLAR in the maintenance treatment of schizophrenia was based on an up to 72-week, multinational, double-blind, placebo-controlled, randomized withdrawal study in the prevention of relapse in adult patients with schizophrenia.
Amgen and Allergan Receive Positive CHMP Opinion for ABP 215 (Biosimilar Bevacizumab) for the Treatment of Certain Types of Cancer
ABP 215 has been recommended for approval for the treatment of certain types of cancer, including in combination with fluoropyrimidine-based chemotherapy for metastatic carcinoma of the colon or rectum.
UroGen Pharma Announces First Patient Enrolled in Allergan Phase II Clinical Trial of RTGel in Combination With BOTOX for the Treatment of Overactive Bladder
The trial is being conducted by Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, under the terms of a license agreement with UroGen Pharma.
Allergan released its third-quarter financials, with mixed results and plans to make fairly major changes.
Allergan Presented New Phase III Data of Ulipristal Acetate in Women with Uterine Fibroids at the ASRM Annual Congress
Allergan presented new analyses of VENUS II, the second of two pivotal Phase III clinical trials evaluating the efficacy and safety of ulipristal acetate (UPA), an investigational drug for the treatment of abnormal uterine bleeding in women with uterine fibroids.
Allergan Receives Approval for Ozurdex (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)
Ozurdex is the first approved intravitreal injection for RVO in China.
Allergan Board of Directors Announces Fourth Quarter 2017 Cash Dividend and Increases Quarterly Cash Dividend for 2018
Allergan today announced the record and payment dates for a cash dividend of $0.70 per ordinary share for the fourth quarter of 2017.
Allergan is a good example of how many mergers and acquisitions over a very short period of time created a large, international company.
Allergan issued the FAQ document following the U.S. District Court's decision on the RESTASIS patents announced earlier this week.
Mylan today announced that the United States District Court for the Eastern District of Texas has issued a 135-page decision finding all asserted claims of the patents relating to Restasis invalid based on obviousness.
Allergan Release: U.S. District Court for the Eastern District of Texas Issues Adverse Trial Decision Concerning RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05% Patents
Allergan today acknowledged that the U.S. District Court for the Eastern District of Texas has issued an adverse trial decision finding that the four asserted patents covering RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05% are invalid.
Allergan Announces Settlement On RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05% Patent Litigation With INNOPHARMA
Allergan Announces That The FDA Accepts New Drug Application For Ulipristal Acetate For Uterine Fibroids